Project Grant HT9425261E345
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $1.9M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Bethesda, MD 20852, USA
Similar Awards
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Johns Hopkins University a $839,475 Project Grant effective July 1, 2026 through June 30, 2028 under the Military Medical Research and Development program (CFDA 12.420) to support research on "Restoring mRNA Decay Homeostasis to Treat Amyotrophic Lateral Sclerosis." The research will be conducted at Johns Hopkins' Baltimore, Maryland facility. This award supports the DHA's mission to transform health care...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded $831,722 through its Military Medical Research and Development program (CFDA 12.420) to Aristotle University of Thessaloniki's Special Account for Research Funds on June 15, 2026, for a two-year project completion deadline of June 14, 2028. The award supports research on oxidized-protein targeted degradation as a first-in-class therapeutic strategy to combat oxidative damage in amyotrophic lateral sclerosis (ALS). This project...
- Federal Grant Award Summary The University of Miami's Office of Research Administration - School of Medicine Division received a $1.0 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded September 30, 2026, with an ultimate completion date of September 29, 2029. The project, titled "Immunoassay Development and Validation of HDGFL2-CE as a Monitoring and Susceptibility/Risk Biomarker in ALS,"...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Washington University Office of Sponsored Research Services a Project Grant of $840,000 under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026, through May 31, 2028. This award supports investigative research examining hyperphosphorylation of tau serine 262 as a novel biomarker and therapeutic target in amyotrophic lateral sclerosis (ALS). The research addresses the DHA's mission...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $352,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research for the project period September 1, 2025, through August 31, 2027. The award supports research focused on augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor in glioblastoma treatment. This research aligns with the DHA's mission to transform healthcare for service...
- Federal Grant Award Summary Emory University's Office of Sponsored Programs received an $840,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective April 1, 2026, through March 31, 2028. The award funds research titled "Repurposing Approved Drugs as First-in-Class Disruptors of the P38/MK2 Complex to Suppress Neuroinflammation in ALS," which investigates therapeutic approaches to amyotrophic...
- Federal Project Grant Award Summary Award Overview: Modulo Bio, Inc. received a $1.74 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded May 1, 2026, with an ultimate completion date of April 30, 2028. This award supports therapeutic development of an NR1H3-targeting antisense oligonucleotide (ASO) designed to treat amyotrophic lateral sclerosis (ALS), a neurodegenerative disease affecting Service...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Washington University Office of Sponsored Research Services a Project Grant totaling $834,915 under the Military Medical Research and Development program (CFDA 12.420) to develop small molecules that disrupt TDP-43 (TAR DNA-binding protein 43) aggregation and restore protein function. The award, dated May 1, 2026, with an ultimate completion date of April 30, 2028, supports basic and applied biomedical research...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Jackson Laboratory a $2.27 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective August 1, 2025, through July 31, 2028. The award funds research focused on mapping the ribonucleic acid (RNA) splicing landscape of neurofibromatosis type 1 (NF1) and characterizing its impact on neurofibromin function across various tissue types. This three-year initiative supports...
- Federal Grant Award Summary Massachusetts General Hospital's Research Management Division received a $839,954 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026 through May 31, 2028. The award funds research on "Augmented Immunomodulatory and Neuroprotective Allogeneic B Cell Therapy for ALS" (amyotrophic lateral sclerosis), a clinical and translational research initiative...